文献速递淋巴瘤

累积蒽环类暴露与心脏毒性风险:一项丹麦全国性队列研究,纳入2440例接受或不接受蒽环类治疗的淋巴瘤患者

Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
PubMed 文献 · Br J Haematol · 2018-11-08

该丹麦全国性队列研究纳入2000-2012年接受一线免疫化疗的弥漫大B细胞淋巴瘤和滤泡性淋巴瘤成人患者2440例,其中1994例(81.7%)接受含蒽环类方案(R-CHOP或R-CHOEP),446例(18.3%)未接受蒽环类(参照组)。与参照组相比,接受3-5周期、6周期及>6周期R-CHOP/CHOEP者充血性心力衰竭(CHF)的校正风险比分别为5.0、6.8和13.4。含蒽环类一线治疗增加无心脏病史患者CHF风险,尤其>6周期者CHF发生率显著增加。

要点

  • 接受3-5、6、>6周期R-CHOP/CHOEP者CHF校正HR分别为5.0、6.8、13.4(参照为未用蒽环类)。
  • 含蒽环类方案者5年CHF累积风险:3-5周期4.6%、6周期4.5%、>6周期7.9%,未用蒽环类者0.8%。
  • 一线淋巴瘤治疗使用蒽环类增加无心脏病史患者的CHF风险,>6周期者风险显著增加。

核心结论

  • 一线淋巴瘤治疗使用蒽环类增加无心脏病史患者的CHF风险,尤其>6周期R-CHOP/CHOEP与CHF发生率显著增加相关。

研究设计与样本

  • 丹麦全国性队列研究,从丹麦淋巴瘤登记处识别2000-2012年接受一线免疫化疗的成人弥漫大B细胞淋巴瘤和滤泡性淋巴瘤患者。
  • 共纳入2440例无既往心脏病史患者,1994例(81.7%)接受含蒽环类化疗(R-CHOP或R-CHOEP),446例(18.3%)未接受蒽环类(参照组)。

主要发现

  • 与参照组相比,3-5周期R-CHOP/CHOEP的CHF校正HR为5.0(95%CI 1.4;18.5),6周期为6.8(95%CI 2.0;23.3),>6周期为13.4(95%CI 4.0;45.0)。
  • 以全因死亡为竞争风险,含蒽环类者5年CHF累积风险:3-5周期4.6%,6周期4.5%,>6周期7.9%;未用蒽环类者为0.8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiotoxicity is a known risk of anthracycline treatment. However, the relative contribution of anthracyclines to the development of congestive heart failure (CHF), when included in a poly-chemotherapy regimen, is unclear. We examined cardiotoxicity in adult patients with diffuse large B-cell lymphoma and follicular lymphoma undergoing first-line immunochemotherapy from 2000-2012. In total, 2440 patients without previous heart disease were identified from the Danish Lymphoma Registry, of which 1994 (81·7%) were treated with anthracycline-containing chemotherapy [R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R-CHOEP (R-CHOP + etoposide)] and 446 (18·3%) were treated without anthracyclines (reference group). Compared to the reference group, the adjusted hazard ratio of CHF after 3-5 cycles of R-CHOP/CHOEP was 5·0 [95% confidence interval (CI) 1·4; 18·5], 6 cycles 6·8 (95% CI 2·0; 23·3) and >6 cycles 13·4 (95% CI 4·0; 45·0). The cumulative 5-year risk of CHF with all-cause mortality as competing risk was 4·6% after 3-5 cycles of R-CHOP/CHOEP, 4·5% after 6 and 7·9% after more than 6 cycles. Cumulative 5-year risk for patients treated without anthracyclines was 0·8%. Using anthracyclines in first-line lymphoma treatment increases risk of CHF in patients without previous history of heart disease. In particular, treatment with >6 cycles of R-CHOP/CHOEP is associated with a significant increase in CHF rate.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Baech J, Hansen SM, Lund PE, et al. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol. 2018. PMID: 30406945. doi:10.1111/bjh.15603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。